LA JOLLA, Calif.--(BUSINESS WIRE)-- CHI-California Healthcare Institute issued the following response today to the U.S. Food and Drug Administration’s (FDA) “Medical Device Innovation Initiative:”
“CHI commends the FDA for its recognition of the need for a more efficient regulatory pathway for innovative medical devices that have the potential to improve lives,” said CHI President and CEO David L. Gollaher, Ph.D. “It is essential that the FDA maintains focus on initiatives that strengthen the medical device review process, bringing greater clarity and consistency, while ensuring the U.S. maintains its competitive edge.”
“We look forward to reviewing the FDA’s new program in further detail and discussing potential implications on biomedical research and development with the Agency.”
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is www.chi.org. Follow us on Twitter @calhealthcare and Facebook.
California Healthcare Institute
Heather Chambers, 858-456-8885
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Medical Devices Research FDA Science